Starboard Details Opposition to Bristol-Myers Deal for Celgene

Australia News News

Starboard Details Opposition to Bristol-Myers Deal for Celgene
Australia Latest News,Australia Headlines
  • 📰 WSJ
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 63%

Activist investor Starboard describes Bristol-Myers Squibb's proposed acquisition of Celgene as poorly conceived and ill advised

Activist investor Starboard Value LP detailed its opposition to Bristol-Myers Squibb Co.’s proposed acquisition of Celgene Corp. and said it plans to organize other shareholders to oppose the $74 billion deal.

In a letter addressed to Bristol-Myers shareholders and released Thursday, Starboard criticized Bristol management and its board for what it said were years of weak performance, saying the drugmaker hasn’t “earned the right, in our view, to execute on a ‘bet the company’ acquisition.”

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJ /  🏆 98. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneActivist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Read more »

Top Bristol-Myers shareholder comes out against $74 billion Celgene dealTop Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Read more »

Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisitionCelgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Read more »

Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Read more »

Novartis and the fixer: New details on a big drug company's deal with ex-Trump lawyer Michael CohenNovartis and the fixer: New details on a big drug company's deal with ex-Trump lawyer Michael CohenIn the Cohen hearing, Rep. Meadows asked for some articles to be entered into the record, including one from the L.A. Times. Here's the piece he was referring to: A column about how the drug company Novartis lied about its relationship with Michael Cohen.
Read more »

Michael Cohen Details Allegations of Trump’s Role in Hush-Money SchemeMichael Cohen Details Allegations of Trump’s Role in Hush-Money SchemePresident Trump and his company’s chief financial officer coordinated with Michael Cohen to pay for the silence of a porn star and conceal Mr. Trump’s role in the deal, using sham invoices to cover it up, Mr. Cohen alleged in testimony to the House Oversight Committee.
Read more »

Beyond 'Bumper Sticker' Slogans: 2020 Democrats Debate Details Of Medicare-For-AllBeyond 'Bumper Sticker' Slogans: 2020 Democrats Debate Details Of Medicare-For-AllPresidential candidates like Bernie Sanders, Kamala Harris and Amy Klobuchar are giving details of their health care proposals, the first big issue where 2020 hopefuls are differentiating themselves.
Read more »

Prosecutors Detail Prostitution Solicitation Charges Against Robert KraftA state attorney’s office in Florida on Monday detailed prostitution solicitation charges against New England Patriots owner Robert Kraft.
Read more »



Render Time: 2025-03-04 14:19:20